Abstract

With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a successful strategy to develop innovative and potent vaccines. Indeed, it offers the potential to increase vaccine potency and/or modulate immune response quality while reducing off-target effects. With mRNA-vaccines establishing themselves as a versatile technology for future applications, in the last years several approaches have been explored to target nanoparticles-enabled mRNA-delivery systems to immune cells, with a focus on dendritic cells. Dendritic cells (DCs) are the most potent antigen presenting cells and key mediators of B- and T-cell immunity, and therefore considered as an ideal target for cell-specific antigen delivery. Indeed, improved potency of DC-targeted vaccines has been proved and . This review discusses the potential specific targets for immune system-directed mRNA delivery, as well as the different targeting ligand classes and delivery systems used for this purpose.

MeSH

Immune System Diseases, Vaccines, Dendritic Cells, Adaptive Immunity, T-Lymphocytes, Antigen-Presenting Cells, Rna, Messenger

Cited by

• The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems. Pharmaceutics, 2024
• mRNA Vaccine Technology Beyond COVID-19. Vaccines (Basel), 2025
• Hydroxychloroquine-Derived Ionizable Lipid Facilitates Spleen-Tropic Transfection and Enhances Cancer Immunotherapy. Chem Bio Eng, 2025
• Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives. Pharmaceutics, 2025
• Innate immune responses to RNA: sensing and signaling. Front Immunol, 2024
• Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems? Vaccines (Basel), 2024
• Prophylactic and therapeutic vaccine development: advancements and challenges. Mol Biomed, 2024
• Immune Modulation with Oral DNA/RNA Nanoparticles. Pharmaceutics, 2025
• Exploration of drug repurposing for Mpox outbreaks targeting gene signatures and host-pathogen interactions. Sci Rep, 2024
• Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2024
• Schmallenberg virus epidemiology and regional control strategies: diagnostics, vaccines, and vector management. Front Cell Infect Microbiol, 2025